Long-term treatment of psoriasis with cyclosporin A-side-effects, minimal effective dose and cyclosporin blood levels
- 1 January 1991
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 16 (1) , 8-10
- https://doi.org/10.1111/j.1365-2230.1991.tb00283.x
Abstract
Fourteen patients with psoriasis received long-term treatment with cyclosporin (CsA). Among patients there was great variability in the minimal effective CsA dose. In most patients long-term treatment was limited due to dose reductions made necessary because of side-effects. The therapeutic window for CsA seems small. CsA blood levels associated with side-effects and with the minimal effective dose are in the same range and correlation between CsA blood levels and effectiveness in psoriasis is weak. Therefore, in CsA therapy for psoriasis, without concomitant medication which may influence CsA blood levels, the measurement of CsA blood levels is not necessarily helpful in optimizing therapy or preventing side-effects.Keywords
This publication has 6 references indexed in Scilit:
- Long-term cyclosporin for psoriasisBritish Journal of Dermatology, 1989
- CHRONIC INJURY OF HUMAN RENAL MICROVESSELS WITH LOW-DOSE CYCLOSPORINE THERAPYTransplantation, 1988
- Low-dose cyclosporin A in severe psoriasis. A double-blind studyBritish Journal of Dermatology, 1988
- Cyclosporine improves psoriasis in a double-blind studyJAMA, 1986
- CORRELATION OF SERUM CYCLOSPORINE CONCENTRATION WITH RENAL DYSFUNCTION IN MARROW TRANSPLANT RECIPIENTSTransplantation, 1985
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978